Aims: Fiveα reductase inhibitor (5ARI) therapy has been associated with sexual dysfunction in some patients. This study assessed the impact of a fixed-dose combination of the 5ARI dutasteride 0.5 mg and the α 1 -adrenoceptor antagonist tamsulosin 0.4 mg (DUT-TAM FDC) on Men's Sexual Health Questionnaire (MSHQ) domain scores in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).
| INTRODUC TI ON
The fixed-dose combination of the 5α-reductase inhibitor (5ARI), dutasteride 0.5 mg, and the α 1 -adrenoceptor antagonist, tamsulosin 0.4 mg (DUT-TAM FDC), is recommended as a first-line treatment for the management of moderate-to-severe lower urinary tract symptoms (LUTS) because of benign prostatic hyperplasia (BPH), in patients at risk of disease progression. 1 However, the potential for sexual dysfunction with 5ARIα 1 -blocker combination therapies can limit their use in clinical practice, despite patient satisfaction with treatment 2 and clinical studies indicating efficacy in reducing symptoms, clinical progression, and the risk of surgery. [3] [4] [5] [6] A systematic review and meta-analysis revealed that erectile dysfunction (ED) and libido alteration were notably more prevalent in patients treated with combination therapy compared with those treated with α 1-blocker monotherapy alone. 7 The risk of ED was higher in those treated with combination therapy but the risk of libido alteration was the same for both patients treated with 5ARI monotherapy and those treated with combination therapy. 7 Although previous research has reported libido alterations as part of the assessment of sexual adverse events (AEs), the discussions within the literature have focused on the effects of 5ARIs on erectile and ejaculatory function. 5, 8 Evidence from epidemiological studies has suggested that it is also important to consider sexual desire and satisfaction when assessing male sexual dysfunction. 9, 10 It should be noted that the assessment of sexual function in most studies in this field has been restricted to spontaneous reporting of sexual AEs, including decreased libido, as part of regular clinical trial AE reporting. [3] [4] [5] [6] 11 Spontaneous AE reporting presents a disadvantage as it is not quantitative. Furthermore, information regarding the onset, character, and resolution of AEs is subject to patients' interpretation and the potential but not uncommon misunderstanding of the domains of sexual function. 12 Another disadvantage of spontaneous AE reporting is its dependence on the patient's decision to mention it during the study visit (without prompt).
Consequently, understanding of the sexual AEs associated with combination therapy is limited.
The validated 25-item Male Sexual Health Questionnaire (MSHQ) was developed for use in a BPH registry to assess specific aspects of male sexual dysfunction. 13 The questionnaire contains three core domains (erection, ejaculation, and satisfaction) and includes additional items related to sexual activity and desire, as well as bother, all of which may be affected by the increased severity of LUTS. 8, 13 Sexual desire is thought to more accurately reflect libido than sexual activity, though the latter can be considered a surrogate marker for libido; therefore, these domains are complimentary.
We recently reported the results of the first domain-specific quantitative evaluation of DUT-TAM FDC therapy on three sexual function domains of the MSHQ. 14 
| MATERIAL S AND ME THODS

| Study design
This post hoc analysis of a double-blind, randomised, placebocontrolled, parallel-group study was conducted at 51 centres across Europe and Australia (GSK116115/NCT01777269) between 18
February 2013 and 5 April 2016. Following a 4-week run-in period, patients were randomised (1:1) to receive once-daily dutasteride 0.5 mg and tamsulosin 0.4 mg (DUT-TAM FDC) or placebo for 12 months.
Lifestyle advice, relevant to maintaining sexual function and improving LUTS, was provided at baseline to subjects in both treatment groups.
The objective of the current analysis was to evaluate the impact of DUT-TAM FDC treatment on libido using the scores for the sexual activity, sexual desire and bother domains of the MSHQ, which were prospectively collected from patients included in the intent-to-treat (ITT) population from the primary analysis.
The primary study was approved by the appropriate regulatory and ethics committees, and performed in accordance with the Declaration of Helsinki 2008 15 and Good Clinical Practice guidelines. 16 Written informed consent was obtained from each patient prior to study participation. 
| Study population
Eligibility criteria for enrollment in the study have been reported previously. 14 Patients with a total serum PSA of >10.0 ng/mL at screening were excluded as were those with a history or evidence of prostate cancer and/or those who had used prohibited medications.
| End-points
The primary study assessed changes in the sexual function domains of the MSHQ over a 12-month study period; details of the primary AEs at the end of the study (after discontinuation of treatment) were followed up via phone call after 6 months.
| Statistical analysis
The sample size was based on the change in the total MSHQ score. 
| RE SULTS
| Study population
As described previously, 14 Figure 1B ).
| MSHQ sexual activity domain
| MSHQ sexual desire domain
In the DUT-TAM FDC therapy group, mean (SD) MSHQ sexual desire domain scores ranged from 9.0 (2.35) to 10.0 (1.77) between baseline and Month 12. Values in the placebo group ranged from 9.7
(1.64) to 9.9 (1.72) (Figure 2A ).
Patients receiving DUT-TAM FDC had a statistically significant (P < 0.05) reduction (worsening) from baseline in adjusted mean MSHQ sexual desire domain scores compared with placebo at Months 6, 9, and 12 (Table 2; Figure 2B ). No statistically significant between treatment group differences were seen at Month 3. The treatment difference observed at Month 1 (P < 0.001) was nominally significant because of the multiplicity step-down procedure employed. Table 3) . Each of these correlations were found to be significant (P < 0.0001).
| MSHQ bother domain
| Domain correlations at baseline
Similar correlations were seen between the sexual desire domain scores and those for the ejaculation (r = 0.40), erection (r = 0.46), and satisfaction domains (r = 0.51) ( Table 3 ). Each of these correlations were also found to be significant (P < 0.0001).
| Safety
As previously reported, the proportion of patients with any AEs, SAEs, and drug-related AEs was significantly higher in the DUT-TAM FDC therapy group than in the placebo group. 14 in the DUT-TAM FDC therapy group compared with 0.6 points in the placebo group (P < 0.001). 14 However, as for MSHQ total score, a minimum clinically meaningful change in ejaculation domain scores is yet to be determined. Previous studies have shown sensitivity of the total MSHQ scores to both diagnostic status and treatment conditions. [17] [18] [19] The post hoc correlation analyses between sexual activity/desire and ejaculation, erection, and satisfaction domains were all in the expected direction, and in line with previously described correlations between sexual desire, erectile dysfunction, and sexual satisfaction. 20 Currently, the potential mechanisms of loss or alteration of libido are unknown. A complex combination of biological, psychological, and social factors contributes to sexual desire. 21 Based on the major influence androgens have on sexual desire, a reduction in libido may indicate androgen deficiency arising from either pituitary or testicular dysfunction, which can be evaluated by measurement of serum testosterone. 22 If testosterone concentrations fall within the normal range, it is unlikely that endocrine factors are responsible for loss of libido. 22 Interestingly, 5ARIs have been shown to elevate serum testosterone concentrations during treatment, 23 which may suggest that endocrine factors are unlikely to be responsible for the loss of libido seen in this study. Serum concentrations of dihydrotestosterone (DHT), a more potent androgen than testosterone, 24 decrease during treatment with 5ARIs because of inhibition of conversion from testosterone. 25 Whether this contributes to loss of libido remains to be elucidated; however, it has been suggested that male sexual function is primarily related to testosterone as opposed to DHT. 26 Evidence to support this comes from male pseudohermaphrodites, who are deficient in DHT and the 5α-reductase type 2 enzyme, but have been reported to have an intact sex-drive. 26, 27 A limitation of the findings presented in this paper is that the 
